In the evolving landscape of early breast cancer (EBC) treatment, the concept of tailoring adjuvant therapy to individual patient risk has become increasingly central. Efforts are ongoing to optimise treatment by escalating therapy in patients at high risk of recurrence. At the same time, there is growing interest in the potential for treatment de-escalation in selected patients, particularly as concerns around quality of life, treatment fatigue, and adherence come into sharper focus. In this context, clinicians are navigating a complex decision-making process that balances efficacy, tolerability, patient preferences and adherence, and emerging data. In this article, Prof. Dr. Ahmad Awada (Chirec Cancer Institute, Brussels) discusses how he approaches treatment optimisation in high-risk EBC and how data from recent trials inform his strategies.
Top
